［1］Marsh JC, Ball SE, Darbyshire P, Gordon-Smith EC, Keidan AJ, Martin A, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia［J］. Br J Haematol, 2003, 123(5):782-801.
［4］Giannakoulas NC, Karakantza M, Theodorou GL, Pagoni M, Galanopoulos A, Kakagianni T, et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anemia patients［J］. Br J Haematol, 2004, 124(1): 97-105.
［5］Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA matched sibling donor transplants for young patients with severe acquired aplastic anemia［J］. Blood, 2007,110(4): 1397-1400.
［7］Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation(BMT) versus immunosuppression for the treatment of severe aplastic anemia(SAA): a report of the EBMT SAA working party［J］. Br J Hanenatol, 1988,70(2):177-182.
［9］Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine［J］.J Pediatr, 2008,153(6): 814-819.
［10］Ganapiev AA, Golubovskaia IK, Zalialov IuR, Estrina MA, Afanas′ev BV.The use of allogeneic bone marrow transplantation and immunosuppressive therapy in the treatment of patients with acquired aplastic anemia［J］. Ter Arkh, 2010,82(7): 48-52.
［12］FrickhofenN, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A:11-year follow-up of a randomized trial comparing treatments of aplastic anemia［J］. Blood, 2003, 101(4): 1236-1242.
